FDA Workshop Summary: Diversity in Clinical Trials Action Plan

Summary

The FDA has published a summary of its recent public workshop on advancing diversity and representation in clinical trials. Key takeaways include enhanced requirements for Diversity Action Plans, community engagement best practices, and anticipated regulatory expectations for enrollment diversity reporting.